Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

Company expects to hold End-of-Phase 2 meeting with the FDA by year-end "We believe the positive data presented today demonstrate clinical proof-of-concept of our novel mRNA platform and highlight the potential of Descartes-08 to provide deep and durable improvements for patients with MG," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "Our recently granted RMAT designation supports the continued development of Descartes-08 in collaboration with the FDA, with plans to hold an ...